tion for women with a proven BRCA1 or BRCA2 mutation is to choose screening "with the main objective to identify ovarian cancer in an early stage to improve prognosis and reduce morbidity and mortality," write Dr. Geertruida H. de Bock and colleagues at the University of Groningen, the Netherlands. </p>
<p>However, the effectiveness of such screening "was disappointing," they report.  The screening exams often missed the cancer completely and all of the ones that were detected were already at an advanced st